| |
|
|
|
|
|
 |
| |
|
µ¥¼ÒÅ©¸°·Î¼Ç0.05%(µ¥¼Ò³ªÀ̵å) 110g DESOCRIN LOT.[Desonide]
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
Á¦Á¶È¸»ç |
°í·ÁÁ¦¾à(ÁÖ)
|
ÆÇ¸Åȸ»ç |
°í·ÁÁ¦¾à(ÁÖ)
|
Çã°¡Á¤º¸ |
ÃëÇÏ
(2020.11.20)
|
BIT ¾àÈ¿ºÐ·ù |
¿Ü¿ë ½ºÅ×·ÎÀ̵å (Steroids : Skin & Mucous Membrane)
|
º¹ÁöºÎºÐ·ù |
264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
642800292 Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó \0 ¿ø/110g/º´(2016.12.01)(ÇöÀç¾à°¡)\5,170 ¿ø/110g/º´(2016.01.01)(º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Desonide / D07AB08 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]

|
÷°¡Á¦ |
°æÁúÀ¯µ¿ÆÄ¶óÇÉ,
±Û¸®¼¼¸±½ºÅ׾Ʒ¹ÀÌÆ® SE,
¶ó¿ì¸±È²»ê³ªÆ®·ý,
¼¼Åº¿Ã,
¼Ò¸£ºñź¸ð³ë½ºÅ׾Ʒ¹ÀÌÆ®,
¼ö»êȳªÆ®·ý,
½ºÅ׾Ƹ±¾ËÄÚ¿Ã,
½ÃÆ®¸£»ê¼öȹ°,
¿¡µ¥Æ®»ê³ªÆ®·ý¼öȹ°,
Á¤Á¦¼ö,
ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿,
ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝ
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
642800292
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/110g/º´(2016.12.01)(ÇöÀç¾à°¡)
\5,170 ¿ø/110g/º´(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö ·Î¼Ç [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
ÀÚ»çÆ÷Àå´ÜÀ§¿¡ µû¸§ |
| ÁÖ¼ººÐÄÚµå |
141540CLT
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¿¡ ¹ÝÀÀÇÏ´Â ÇǺÎÁúȯÀÇ °¡·Á¿ò ¹× ¿°ÁõÀÇ °æ°¨
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
-ȯºÎÀÇ »óÅ¿¡ µû¶ó 1ÀÏ 2 ¡ 3ȸ ¾ã°Ô ¹Ù¸¥´Ù.
-ÀÌ ¾àÀº Àß Èçµé¾î¼ »ç¿ëÇÑ´Ù.
-´Ù¸¥ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¿Í ¸¶Âù°¡Áö·Î »óŰ¡ È£ÀüµÉ °æ¿ì Ä¡·á¸¦ Áß´ÜÇØ¾ß ÇÑ´Ù.
-¸¸¾à 2ÁÖ À̳»¿¡ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì Áø´ÜÀÇ ÀçÆò°¡°¡ ÇÊ¿äÇÏ´Ù.
-ÀÌ ¾àÀº ¹ÐºÀºØ´ë¿ä¹ýÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ ´ëÇÏ¿© °ú¹Î¹ÝÀÀ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
2) ÇǺÎÀÇ °áÇÙ µîÀÇ ¼¼±Õ, Áø±Õ, ¹ÙÀÌ·¯½º ¹× ±â»ýÃæ °¨¿° ºÎÀ§(´Ü¼øÆ÷Áø, ¿ìµÎÁõ, ¼öµÎ Æ÷ÇÔ)
3) ¾È°ú¿ëÀ¸·Î »ç¿ëÇÏÁö ¸» °Í(³ì³»ÀåÀÇ À§Çè).
4) ±Ë¾çÈµÈ º´¼Ò, ¿©µå¸§, ÁÖ»ç(rosacea)
5) 1¼¼ ÀÌÇÏÀÇ ¿µ¾Æ |
| ½ÅÁßÅõ¿© |
1) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º, ¼öÀ¯ºÎ
2) À¯¡¤¼Ò¾Æ
3) °í·ÉÀÚ
4) ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
1) ÀÓ»ó½ÃÇè¿¡¼ ÀÌ ¾à°ú °ü·ÃµÈ ÀÌ»ó¹ÝÀÀÀÇ ÃÑ ¹ßÇöÀ²Àº ¾à 8 %¿´´Ù. ÀÌ´Â ÀÚÅë°ú ÀÛ¿°¨ÀÌ ¾à 3 %, Àڱذ¨, Á¢ÃËÇǺο°, »óžÇÈ, ÇǺιڸ®, °¡·Á¿òÁõ, ½ÉÇÑ ÀϽÃÀûÀÎ È«¹Ý°ú °ÇÁ¶°¨/Àμ³ÀÌ °¢°¢ 2 % ÀÌÇÏ¿´´Ù.
2) ´Ù¸¥ ±¹¼Ò ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¿Í ¸¶Âù°¡Áö·Î ´ÙÀ½°ú °°Àº ±¹¼Ò ÀÌ»ó¹ÝÀÀÀÌ µå¹°°Ô º¸°íµÇ¾ú°í ÀÌ´Â ¹ÐºÀºØ´ë¿ä¹ýÀ» ½Ç½ÃÇÒ ¶§, ƯÈ÷ È¿´ÉÀÌ °ÇÑ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¸¦ »ç¿ëÇÒ¼ö·Ï ´õ ÀÚÁÖ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. : ¸ð³¶¿°, ´Ù¸ðÁõ, ¿©µå¸§¸ð¾ç ¶Ç´Â ³óÆ÷¼º ¹ßÁø, »ö¼ÒÄ§ÂøÀúÇÏ, ÀÔÁÖÀ§ ÇǺο°, 2Â÷ °¨¿°, ÇǺÎÀ§Ãà(ƯÈ÷ ¼Õ, ¹ß ³¡ºÎºÐ), ÇǺÎÀ§Ãà¿¡ µû¸¥ ÀÌÂ÷ÀûÀÎ ¹Ý»ó ÃâÇ÷ÀÚ»ö¹Ý, ¼±Á¶Áõ, ¶¡¶ì, ¸ð¼¼Ç÷°üÈ®Àå(ƯÈ÷ ¾ó±¼), ÇǺÎÃë¾à, ÁÖ»ç¾ÇÈ, À̿ϼº »óóÀÇ ¹ÝÈçÈ Áö¿¬, ¿åâ±Ë¾ç, ÇÏÁö±Ë¾ç, ½Ã¾ß È帲
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(desonide; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Desonide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
|
| Pharmacology |
Desonide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
|
| Metabolism |
Desonide¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Desonide¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Absorption |
Desonide¿¡ ´ëÇÑ Absorption Á¤º¸ Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
|
| Pharmacokinetics |
DesonideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ¹ÐºÀ¿ä¹ýÀ̳ª ¿°Áõ ÀÖ´Â ºÎÀ§¿¡ Àû¿ë½Ã Èí¼ö°¡ Ä¿Áü.
- ´ë»ç : °£¿¡¼ ´ë»çµÊ.
- ¹è¼³ : ÁÖ·Î ½ÅÀåÀ¸·Î ¹è¼³µÊ.
- È¿°ú ¹ßÇö : ÇǺÎÁúȯ½Ã °æÇÇÁ¦·Î 7ÀÏÀ̳» È¿°ú ¹ßÇöÇÔ.
|
| Biotransformation |
Desonide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Desonide¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Desonide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Desonide¿¡ ´ëÇÑ Description Á¤º¸ A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem]
|
| Drug Category |
Desonide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-inflammatory Agents
|
| Smiles String Canonical |
Desonide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO
|
| Smiles String Isomeric |
Desonide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
|
| InChI Identifier |
Desonide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
|
| Chemical IUPAC Name |
Desonide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-11-01
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|